These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1111 related items for PubMed ID: 23800322

  • 1. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [Abstract] [Full Text] [Related]

  • 2. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S.
    J Alzheimers Dis; 2013 Dec; 35(1):137-46. PubMed ID: 23364139
    [Abstract] [Full Text] [Related]

  • 3. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S.
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [Abstract] [Full Text] [Related]

  • 4. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM.
    J Alzheimers Dis; 2010 Oct; 22(1):87-95. PubMed ID: 20847452
    [Abstract] [Full Text] [Related]

  • 5. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.
    J Alzheimers Dis; 2011 Oct; 27(2):377-84. PubMed ID: 21841257
    [Abstract] [Full Text] [Related]

  • 6. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
    Babić Leko M, Borovečki F, Dejanović N, Hof PR, Šimić G.
    J Alzheimers Dis; 2016 Oct; 50(3):765-78. PubMed ID: 26836160
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Oct; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 8. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 9. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2007 Jul 28; 12(7):671-80. PubMed ID: 17339876
    [Abstract] [Full Text] [Related]

  • 10. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M, Londos E, Minthon L, Nielsen HM.
    J Alzheimers Dis; 2012 Jul 28; 29(1):125-32. PubMed ID: 22207004
    [Abstract] [Full Text] [Related]

  • 11. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Dement Geriatr Cogn Disord; 2005 Jul 28; 19(2-3):164-70. PubMed ID: 15637452
    [Abstract] [Full Text] [Related]

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.
    Lancet Neurol; 2011 Mar 28; 10(3):230-40. PubMed ID: 21317042
    [Abstract] [Full Text] [Related]

  • 13. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M.
    Brain Res; 2009 Jan 28; 1251():1-6. PubMed ID: 19071095
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B, Groblewska M, Zboch M, Muszyński P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P.
    J Alzheimers Dis; 2015 Jan 28; 43(3):1031-7. PubMed ID: 25159667
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S.
    J Alzheimers Dis; 2013 Jan 28; 36(4):759-67. PubMed ID: 23666174
    [Abstract] [Full Text] [Related]

  • 16. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M.
    J Alzheimers Dis; 2011 Jan 28; 24(2):383-91. PubMed ID: 21297274
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A.
    Dement Geriatr Cogn Disord; 2013 Jan 28; 36(1-2):99-110. PubMed ID: 23860354
    [Abstract] [Full Text] [Related]

  • 18. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.
    J Neurol Neurosurg Psychiatry; 2010 Jun 28; 81(6):608-10. PubMed ID: 20522869
    [Abstract] [Full Text] [Related]

  • 19. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, Bloem BR, Verbeek MM.
    Alzheimers Dement; 2014 Jul 28; 10(4):448-455.e2. PubMed ID: 24239248
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2015 Jun 28; 72(6):656-65. PubMed ID: 25867677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.